Business Wire India Nadofaragene firadenovec is the first and only non-replicating gene therapy administered intravesically, and it is already approved and launched in the US This represents the first filing of a novel non-chemotherapy approach in non-muscle invasive bladder cancer (NMIBC) treatment In the Japanese Phase 3 clinical trial,
Ferring Japan announces PMDA Acceptance of NDA Filing for nadofaragene firadenovec
